Table 1.
Summary of treatment groups
| Group | Exosome source | Diabetic status of VSMC source | Pre-treatment of VSMC |
|---|---|---|---|
| Cell studies | |||
| Ctrl | PBS | ||
| NVE | HCASMCs | Non-Diabetic | Non-targeting oligo |
| NVE+KD | HCASMCs | Non-Diabetic | miR-221/222 siRNA |
| DVE | HCASMCs | Diabetic | Non-targeting oligo |
| DVE+KD | HCASMCs | Diabetic | miR-221/222 siRNA |
| Animal study | |||
| Ctrl | Saline | ||
| NVE | NONcNZO10 murine VSMCs | Non-Diabetic | None |
| DVE | NONcNZO10 murine VSMCs | Diabetic | None |
VSMC: Vascular smooth muscle cell; Ctrl: Control; PBS: Phosphate buffered saline; HCASMCs: Human coronary artery smooth muscle cells; NVE: Non-diabetic VSMC derived exosome; DVE: Diabetic VSMC derived exosome; +KD: miR-221/222 knockdown